 Oncolytics Biotech Inc NASDAQ: ONCY has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck Co Inc NYSE: MRK Keytruda pembrolizumab in pancreatic cancer. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting. 